Friday 13th August 2004 |
Text too small? |
One company with loads of groundbreaking research behind it; a ton of potential but no actual earnings is Pacific Edge Biotechnology.
Pacific Edge has been developing products for cancer treatment, an area of research where progress can be measured in years.
The shares have jumped up and down a bit lately on news that the company is close to signing a breakthrough deal with a Japanese pharmaceutical company, which could offer multimillion-dollar investment.
This is pretty good news because at balance date in March the company's capital was $9.62 million, accumulated deficit was $7.09 million, leaving shareholders' equity of $2.52 million.
That has since been boosted by a private placement of six million shares, raised by brokers Forsyth Barr.
But the company is burning through $1.4 million a year, according to chairman Trevor Scott.
If the Japanese deal goes through, and the company is negotiating with two other firms there as well, Pacific Edge could secure development work for at least four years and be able to fund more oncology tests.
The company, based near the University of Otago, has developed an extensive oncology database to correlate clinical information on cancer progression.
No comments yet
May 8th Morning Report
NZ-UAE free trade on the table
ANZ - 2024 Half Year Results Documents
FWL - Foley Wines Limited 2024 Harvest
IKE Closes Major Multi-Year Subscription Deals
AIA - 2024 Macquarie Australia Conference Overview of AIA
Devon Funds Morning Note - 06 May 2024
EROAD FY24 Results and Webinar Details
thl reduces FY24 NPAT guidance
May 6th Morning Report